The company is focusing on new technologies, including mRNA, and expects the vaccines business to deliver a high single-digit sales CAGR over the next five years.
Despite missing the first COVID-19 vaccine wave, GlaxoSmithKline plc hopes to ride the cresting interest in the vaccine sector as it looks to maintain its leadership position in the field through the next decade. GSK aims to launch five new vaccines by 2026, management said during an investor overview on 23 June.
The growth outlook for vaccines centers on the expansion of its blockbuster Shingrix shingles vaccine, building out the meningitis franchise...
The approval for young children, consistent with the FDA’s new COVID-19 vaccine policy, restricts Spikevax to those with conditions putting them at higher risk.
Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.
Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.
With positive relative efficacy data for its mRNA seasonal flu shot, Moderna hopes to file mRNA-1010 for US approval and refile a COVID-19/flu combo shot that it withdrew in May.
